A pharmaceutical is any substance intended to diagnose, cure, treat, or prevent disease in humans or animals. Under U.S. federal law, the definition also covers products designed to affect the structure or function of the body, even if they don’t target a specific disease. That broad legal definition is what separates a pharmaceutical from a cosmetic (which only alters appearance) or a food (which provides nutrition). If a product claims to do something medical, it’s regulated as a drug.
How Pharmaceuticals Are Legally Defined
The Federal Food, Drug, and Cosmetic Act draws a clear line based on intended use. A moisturizer that claims to “beautify” your skin is a cosmetic. The same moisturizer claiming to “treat eczema” becomes a drug and must meet an entirely different set of safety and efficacy requirements before it can be sold. This distinction matters because pharmaceuticals must go through rigorous testing and regulatory review, while cosmetics generally do not.
The intended-use test also means that some products fall into both categories. An anti-dandruff shampoo, for example, cleanses hair (cosmetic function) and treats dandruff (drug function), so it must comply with regulations for both.
Two Main Types: Small Molecules and Biologics
Traditional pharmaceuticals are small-molecule drugs, meaning they’re manufactured through chemical synthesis. Their production process is well defined, yields large uniform batches, and typically involves 40 to 50 critical quality tests per batch. These are the tablets, capsules, and liquids most people picture when they think of medication.
Biologics are a newer, rapidly growing category. They can only be produced by living systems (cells, bacteria, yeast) and are much larger, more complex molecules that may contain hundreds of amino acids. Because they’re made by living organisms, their structure can vary depending on the cell system used, the fermentation conditions, and even the temperature during production. A single batch of a biologic might require 250 or more quality tests. Biologics are also extremely sensitive to heat, light, and physical stress, which makes manufacturing, shipping, and storing them far more challenging than traditional drugs.
This complexity explains why biologics tend to be more expensive. Scaling up production from lab quantities to commercial batches while maintaining purity and consistency is one of the hardest problems in pharmaceutical manufacturing.
How Drugs Are Classified
The World Health Organization maintains the Anatomical Therapeutic Chemical (ATC) system, which organizes every active substance into groups based on the organ or body system it targets and its therapeutic, pharmacological, and chemical properties. The system has five levels of increasing specificity, starting with 14 broad anatomical groups (like “cardiovascular system” or “nervous system”) and drilling down to individual chemical substances. Each drug gets one ATC code based on its main therapeutic use and route of administration.
Countries also classify drugs by legal access. In the U.S., the Controlled Substances Act groups drugs with abuse potential into five schedules, while non-controlled drugs are split into prescription-only and over-the-counter categories.
From Lab to Pharmacy: The Development Process
Bringing a new pharmaceutical to market follows a structured path that typically takes over a decade. It starts with discovery and development in the laboratory, where researchers identify promising compounds. Those candidates then move into preclinical research, where laboratory and animal testing answers basic safety questions before the drug ever reaches a human.
Clinical research, the longest and most expensive phase, tests the drug in people across three stages. Phase I trials evaluate safety in a small group of volunteers. Phase II trials test effectiveness and side effects in a larger group of patients with the target condition. Phase III trials expand to hundreds or thousands of patients to confirm effectiveness, monitor side effects, and compare the drug to existing treatments.
Only about 13.8% of drugs that enter Phase I trials eventually win approval, based on an analysis of more than 15,000 drug development programs spanning 16 years. That means roughly six out of every seven drugs that reach human testing will fail along the way.
Once a company submits all its data, the regulatory agency conducts a thorough review before deciding whether to approve the drug. Even after approval, safety monitoring continues indefinitely.
What It Costs to Develop a Drug
Estimates for the total cost of developing a single new drug range from $314 million to $4.46 billion, depending on the therapeutic area and how the analysis accounts for the cost of capital and failed attempts. A JAMA Network Open study found that factoring in failures and financing costs multiplied the price tag by a factor of five compared to looking only at successful programs. These costs are a major reason new brand-name drugs carry high price tags.
Generic Drugs and Bioequivalence
When a brand-name drug’s patent expires, other manufacturers can apply to produce a generic version. They don’t need to repeat years of clinical trials. Instead, they must demonstrate that their product is bioequivalent to the original, meaning the body absorbs it at the same rate and to the same extent. Regulators compare blood concentration levels of the active ingredient between the generic and the brand-name product. If there’s no significant difference, the generic is considered therapeutically equivalent.
In some cases, a generic may absorb at a slightly different rate but still be approved if that difference is intentional (for example, in an extended-release formulation), reflected in the labeling, and considered medically insignificant.
Who Regulates Pharmaceuticals
Every major market has its own regulatory body. In the United States, the Food and Drug Administration (FDA) oversees the safety, efficacy, and security of human and veterinary drugs, biologics, and medical devices. In Europe, the European Medicines Agency (EMA) evaluates medicines and provides recommendations on quality and safety for the entire European Union. Japan relies on the National Institute of Health Sciences (NIHS) for evaluating pharmaceutical quality and safety, along with the National Institute of Infectious Diseases for antibiotics and vaccines.
These agencies don’t just approve drugs and walk away. The FDA, for instance, runs the Adverse Event Reporting System (FAERS), a database that tracks safety problems with every approved drug and biologic. Health professionals and patients can voluntarily report serious reactions through the MedWatch program, and manufacturers are legally required to submit adverse event reports. Companies must also file reports when manufacturing errors or quality deviations occur.
The Biggest Pharmaceuticals on the Market
The pharmaceutical landscape shifts as new drugs gain traction and older blockbusters lose patent protection. Based on 2024 sales figures, the five highest-grossing drugs were Ozempic (a diabetes and weight-loss injection) at $18.7 billion, Dupixent (used for eczema, asthma, and other inflammatory conditions) at $15.1 billion, Biktarvy (an HIV treatment) at $13.4 billion, the Jardiance family of diabetes and heart failure medications at $13 billion, and Skyrizi (an immune-related treatment for psoriasis and Crohn’s disease) at $11.7 billion.
The dominance of injectable biologics and specialty drugs in this list reflects a broader industry shift. Many of the top-selling pharmaceuticals today are biologics targeting specific immune pathways or metabolic processes, rather than the traditional small-molecule pills that dominated the market a generation ago.